explor
differ
biologist
research
henc
crossov
knowledg
transvers
approach
consider
hamper
even
advent
metagenom
microbiota
virom
usual
studi
separ
differ
team
instanc
among
public
retriev
isi
web
scienc
use
viru
bacteria
independ
keyword
ca
still
found
use
term
concurr
three
recent
articl
describ
compound
bacteri
origin
could
inhibit
replic
virus
vitro
tabl
wang
et
al
zhou
et
al
observ
teicoplanin
semisynthet
glycopeptid
use
clinic
activ
gramposit
bacteria
could
inhibit
ebola
envelop
pseudotyp
virus
teicoplanin
complex
ferment
product
origin
actinoplan
teichomyceticu
actinobacteria
member
exert
bactericid
effect
inhibit
bacteri
cell
wall
biosynthesi
work
wang
et
al
use
pseudotyp
ebola
virus
contain
luciferas
report
gene
screen
us
food
drug
administr
fda
approv
compound
detect
teicoplanin
significantli
inhibit
vero
cell
infect
pseudotyp
ebola
virus
wang
et
al
note
teicoplanin
alreadi
report
activ
envelop
virus
observ
drug
inact
three
picornavirus
nonenvelop
virus
inhibit
pseudotyp
ebola
viru
test
viral
adsorpt
cell
surfac
taken
togeth
data
suggest
teicoplanin
block
viral
entri
step
second
studi
zhou
et
al
test
fdaapprov
drug
also
observ
teicoplanin
inhibit
cell
infect
pseudotyp
ebola
virus
team
found
evid
teicoplanin
target
locat
host
cell
cathepsin
l
perform
glycoprotein
proteolysi
requir
membran
fusion
entri
step
ebola
virus
sarscov
final
teicoplanin
glycopeptid
antibiot
includ
dalbavancin
oritavancin
telavancin
vancomycin
found
inhibit
entri
ebola
viru
sarscov
merscov
transcriptionand
replicationcompet
viruslik
particl
third
studi
varghes
et
al
identifi
ivermectin
abamectin
activ
chikungunya
viru
drug
deriv
avermectin
produc
bacterium
streptomyc
avermitili
whose
discoveri
award
nobel
prize
medicin
ivermectin
abamectin
macrocycl
lacton
wellknown
broad
activ
spectrum
parasit
ivermectin
wide
use
human
veterinari
medicin
wherea
abamectin
use
agricultur
crop
varghes
et
al
use
fulli
autom
chikungunyareplicon
cell
linebas
assay
screen
panel
compound
includ
clinic
approv
drug
well
drug
clinic
trial
found
ivermectin
abamectin
inhibit
chikungunya
viru
replic
dosedepend
manner
decreas
synthesi
genom
rna
antigenom
rna
protein
viru
addit
drug
also
effici
semliki
forest
viru
sindbi
viru
two
alphavirus
yellow
fever
viru
flaviviru
suggest
broad
antivir
activ
three
articl
recent
exampl
report
antivir
activ
drug
bacteri
origin
previous
teicoplanin
alreadi
report
activ
hiv
hepat
c
viru
flavivirus
coronavirus
respiratori
syncyti
viru
influenza
viru
addit
ivermectin
previous
shown
inhibit
helicas
three
flavivirus
name
yellow
fever
viru
dengu
viru
west
nile
viru
tabl
among
exampl
drug
bacteri
origin
activ
virus
previou
work
show
activ
valinomycin
cyclododecadepsipeptid
produc
streptomyc
sarscov
bacteriocin
produc
enterococcu
faecium
herp
simplex
viru
find
make
biolog
sens
virus
current
consid
abund
biolog
entiti
earth
estim
outnumb
bacteria
eukaryot
respect
viral
divers
appear
tremend
still
larg
untap
moreov
recent
technolog
advanc
includ
highthroughput
sequenc
metagenom
culturom
emphasis
concurr
presenc
environment
sampl
well
human
virus
bacteria
archaea
eukaryot
indic
bacteria
may
compet
fight
among
also
multipl
virus
among
virus
wellknown
bacteria
killer
bacteriophag
major
impact
environment
bacteri
commun
propos
treat
bacteri
infect
human
convers
past
decad
crispr
discov
bacteria
amaz
mechan
adapt
immun
invad
virus
demonstr
war
bilater
therefor
hypothesis
bacteria
could
develop
concurr
antibiot
antivir
nonetheless
whilst
fact
microb
interact
fight
among
forefront
decad
bacteriolog
capabl
threaten
viral
replic
wide
overlook
studi
wang
et
al
zhou
et
al
varghes
et
al
first
step
toward
possibl
use
antibiot
antiparasit
drug
deriv
bacteria
antivir
may
repres
anoth
exampl
benefit
drug
repurpos
result
confirm
determin
whether
concentr
within
therapeut
rang
achiev
target
virus
nonetheless
studi
highlight
potenti
antivir
activ
antimicrobi
may
untap
anoth
lesson
articl
regard
strategi
chosen
discov
drug
antivir
effect
inde
hypothesi
predict
model
made
contrast
strategi
straightforward
consist
massiv
highthroughput
screen
hundr
thousand
avail
drug
regardless
known
activ
spectrum
target
approv
indic
differ
approach
specif
target
stage
viru
replic
cycl
block
protein
involv
progress
addit
asid
great
interest
approv
drug
potenti
treatment
viral
infect
current
lack
antivir
usual
case
teicoplanin
ivermectin
consider
experi
use
human
could
acceler
access
clinic
summari
recent
find
open
wide
new
field
fight
viral
infect
highlight
fact
research
bacteriolog
virolog
tightli
compartmentalis
show
done
antibiot
variou
field
mimick
live
probabl
valuabl
strategi
improv
expand
antivir
armamentarium
fund
none
compet
interest
none
declar
ethic
approv
requir
